Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: Comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: Results from the REPOSI study

Drugs and Aging

Volumn 30, Issue 2, 2013, Pages 103-112

  Pasina, Luca ^a   Djade, Codjo D ^a   Lucca, Ugo ^a   Nobili, Alessandro ^a   Tettamanti, Mauro ^a   Franchi, Carlotta ^a   Salerno, Francesco ^b   Corrao, Salvatore ^c   Marengoni, Alessandra ^d   Iorio, Alfonso ^e   Marcucci, Maura ^e   Violi, Francesco ^f   Mannucci, Pier Mannuccio ^g  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ATENOLOL; CARBIDOPA PLUS LEVODOPA; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; FUROSEMIDE; HALOPERIDOL; ISOSORBIDE; METOPROLOL; NIFEDIPINE; OLANZAPINE; PAROXETINE; PRAMIPEXOLE; PREDNISONE; PSEUDOEPHEDRINE; QUETIAPINE; RANITIDINE; TRIAMTERENE; WARFARIN;

AGE; AGED; ANTICHOLINERGIC COGNITIVE BURDEN SCALE; ANTICHOLINERGIC RISK SCALE; ARTICLE; BARTHEL INDEX; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EXPOSURE; DRUG USE; EDUCATION; FEMALE; FUNCTIONAL STATUS; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; SEX; SHORT BLESSED TEST; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 84876274675     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0044-x     Document Type: Article

References (51)

1. Veehof LJG, Stewart RE, Haaijer-Raskamp FM, et al. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17:261-7.
2. Gurwitz JH. Polypharmacy. A new paradigm for quality drug therapy in the elderly? Arch Intern Med. 2004;164:1957-9.
3. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345-51.
4. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86-98.
5. Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516-23.
6. Koh Y, Kutty FBM, Li SC. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag. 2005;1:39-48.
7. Lund BC, Camahan RM, Egge JA, et al. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010. doi: 10.1345/aph.1M657.
8. Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity. 2011;1:28-44.
9. Flacker JM, Cummings V, Mach JR Jr, et al. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry. 1998;6(1):31-41.
10. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(suppl 21):11-4.
11. Hanlon JT, Schamder KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc. 2002;50:26-34.
12. Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc. 2007;55:1248-53.
13. Castelino RL, Bajorek BV, Chen TF. Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services. Ann Pharmacother. 2009;43:1096-106.
14. Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010;75:152-9.
15. Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, dementia in an elderly general population-the 3-City study. Arch Intern Med. 2009;169:1317-24.
16. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60(2):198-203.
17. Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13(6):535-8.
18. Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2005;59(2):143-51.
19. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50(5):836-42.
20. Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099-105.
21. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28.
22. Aizenberg D, Sigler M, Weizman A, et al. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr. 2002;14(3):307-10.
23. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455-9.
24. Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther. 2007;81(2):235-41.
25. Low LF, Anstey KJ, Sachdev P. Use of medication with anticholinergic properties and cognitive function in a young-old community sample. Int Geriatr Psychiaty. 2009;24:578-84.
26. Atkin PA, Veitch PC, Veitch EM, et al. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging. 1999;14(2):141-52.
27. Hutchinson TA, Flegel KM, Kramer MS, et al. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis. 1986;39(7):533-42.
28. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older person. Arch Intern Med. 2008;168(5):508-13.
29. Buostani M, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-20.
30. Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22(6):597-602.
31. Marengoni A, Corrao S, Nobili A, et al. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. Int J Geriatr Psychiatry. 2011;26(9):930-6.
32. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205-10.
33. Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67(5):507-19.
34. Marcucci M, Iorio A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med. 2010;21(6):516-23.
35. Marengoni A, Corrao S, Nobili A, et al. The participating units and co-authors are listed in the Appendix. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. Int J Geriatr Psychiatry. 2010.
36. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130-7.
37. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42(8):703-9.
38. Katzman R, Brown T, Fuld P, et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734-9.
39. Hickie C, Snowdon J. Depression scales for the elderly: GDS, Gilleard, Zung. Clin Gerontol. 1987;6(3):51-3.
40. Carnahan RM, et al. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: association with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481-6.
41. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(9):1159-65.
42. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477-83.
43. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer's type and age-matched controls: a dose response study. Arch Gen Psychiatry. 1987;44:418-26.
44. Fox C, Livingstone G, Maidment I, et al. The impact of anticholinergic burden in Alzheimer's dementia-the laser AD study. Age Ageing. 2011;40:730-5.
45. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-24.
46. Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72-83.
47. Chang CB, Chan DC. Comparison of published explicit criteria for potentially inappropriate medications in older adults. Drugs Aging. 2010;27(12):947-57.
48. Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43:2457-65.
49. Torijesen I. Anticholinergic effects of common drugs are associated with increased mortality in over 65s. BMJ. 2011;342:d3514.
50. Campbell N, Perkins A, Hui S, Khan B, Boustani M. Association between prescribing of anticholinergic medications and incident delirium: a cohort study. J Am Geriatr Soc. 2011;59(Suppl 2):S277-81. doi: 10.1111/j.1532-5415. 2011.03676.x.
51. Flacker JM, Wei JY. Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci. 2001;56(6):M353-5.